TSAAI 2016 Annual Meeting

Pigeon Forge, TN US
August 5, 2016 to August 7, 2016

Target Audience

Allergists, Nurse Practitioners, Physician Assistants, Fellows-in-Training

Learning Objectives

At the conclusion of this activity, participates should be able to:

  • Evaluate and treat patients with common variable immunodeficiency
  • Describe the immunologic pathogenesis of eosinophilic esophagitis
  • Recognize asthma patients who require monoclonal antibody treatments
  • Distinguish the difference between the pathophysiology of IgE mediated vs non-IgE mediated anaphylactic episodes
  • Identify knowledge gaps related to inhaled corticosteroids dosing and side effect recognition and treatment
  • Evaluate and optimize office/patient workflow with electronic medical records


Additional information


TSAAI Annual Meeting 2016

August 5 - 7, 2016 * Pigeon Forge, TN


Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.


All identified conflicts of interest have been resolved.

Mark Ballow, MD

Advisory Council:  Balalta, CSL Behring, Grifols.  Speaker:  Baxalta, CSL Behring.  Research Grant:  CSL Behring.  Honorarium: Baxalta.  Other/DSMB:  Promedic.

J. Andrew Bird, MD

Consulting/Advisory Board:  Aimmune.  Speaker:  DBV Technologies.  Research Grant:  DBV Technologies, Aimmune, FARE.

Phillip Lieberman, MD

Consulting/Advisory Board:  AstraZeneca, Genentech, Meda, Mylan, Novartis, Sanofi, EMD Serono, Teva.  Speaker:  Genentech, Meda, Mylan, Teva.

David Skoner, MD

Consultant:  Greer, Meda, Merck, Sunovion, Mylan, Teva.  Speaker:  Genentech, Greer, Meda, Merck, Novartis, Sunovion.  Research Grant:  GlaxoSmithKline, Genentech, Greer, Merck, Novartis, Sunovion, Teva.

S. Bobo Tanner, MD

Speaker:  BMS, Pfizer.  Research Grant:  GSK, Novartis.

*Tidence Prince, MD

Speaker/Honorarium:  AstraZeneca, Baxalta, CSL Behring, Meda, Novartis, Teva.


The following have no relevant financial relationships to disclose:

Nabeel Farooqui, MD

Reba Green, Meeting Coordinator



*Program Chair and Physician Planner










Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
Course expires: 
Event starts: 
08/05/2016 - 6:30pm CDT
Event ends: 
08/07/2016 - 11:30am CDT
Dollywood's DreamMore Conference Center
2525 DreamMore Way
Pigeon Forge, TN 37863
United States

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.